Search in:

OncoImmunology Volume 6, 2017 - Issue 12

Submit an article Journal homepage

Free access

1,524

Views

CrossRef citations to date

Altmetric

Editorial

CARs on a highway with roadblocks

Lorenzo GalluzziDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA;Sandra and Edward Meyer Cancer Center, New York, NY, USA;Université Paris Descartes/Paris V, Paris, FranceCorrespondence[email protected]

Peter MartinDivision of Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA

Article: e1388486 | Received 29 Sep 2017, Accepted 30 Sep 2017, Published online: 30 Oct 2017

Cite this article
https://doi.org/10.1080/2162402X.2017.1388486
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions
View PDF PDF

References

Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168:724–40. doi:10.1016/j.cell.2017.01.016. PMID:28187291
PubMed Web of Science ®Google Scholar
CAR T-cells: an exciting frontier in cancer therapy. Lancet. 2017;390:1006. doi:10.1016/S0140-6736(17)32395-4.
Web of Science ®Google Scholar
Pagel JM, West HJ. Chimeric Antigen Receptor (CAR) T-Cell Therapy. JAMA Oncol. 2017. doi:10.1001/jamaoncol.2017.2989. PMID:28880983
PubMedGoogle Scholar
Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10:267–76. doi:10.1038/nrclinonc.2013.46. PMID:23546520
PubMed Web of Science ®Google Scholar
Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13:370–83. doi:10.1038/nrclinonc.2016.36. PMID:27000958
PubMed Web of Science ®Google Scholar
van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14:499–509. doi:10.1038/nrd4597. PMID:26129802
PubMed Web of Science ®Google Scholar
Watanabe N, Bajgain P, Sukumaran S, Ansari S, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology. 2016;5:e1253656. doi:10.1080/2162402X.2016.1253656. PMID:28180032
PubMed Web of Science ®Google Scholar
Buque A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, et al. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4:e1008814. doi:10.1080/2162402X.2015.1008814. PMID:26137403
PubMed Web of Science ®Google Scholar
Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16:566–81. doi:10.1038/nrc.2016.97. PMID:27550819
PubMed Web of Science ®Google Scholar
Davenport AJ, Jenkins MR, Ritchie DS, Prince HM, Trapani JA, Kershaw MH, Darcy PK, Neeson PJ. CAR-T cells are serial killers. Oncoimmunology. 2015;4:e1053684. doi:10.1080/2162402X.2015.1053684. PMID:26587330
PubMed Web of Science ®Google Scholar
Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517–28. doi:10.1016/S0140-6736(14)61403-3. PMID:25319501
PubMed Web of Science ®Google Scholar
Aranda F, Buque A, Bloy N, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Spisek R, et al. Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology. 2015;4:e1046673. doi:10.1080/2162402X.2015.1046673. PMID:26451319
PubMed Web of Science ®Google Scholar
Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther. 2010;18:666–8. doi:10.1038/mt.2010.31. PMID:20357779
PubMed Web of Science ®Google Scholar
Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843–51. doi:10.1038/mt.2010.24. PMID:20179677
PubMed Web of Science ®Google Scholar
Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2017. doi:10.1038/nrclinonc.2017.148. PMID:28925994
PubMedGoogle Scholar
Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321–30. doi:10.1182/blood-2016-04-703751. PMID:27207799
PubMed Web of Science ®Google Scholar
Ma G, Shimada H, Hiroshima K, Tada Y, Suzuki N, Tagawa M. Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China. Drug Des Devel Ther. 2009;2:115–22. PMID:19920899
PubMedGoogle Scholar
Pol J, Buque A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, et al. Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology. 2016;5:e1117740. doi:10.1080/2162402X.2015.1117740. PMID:27057469
PubMed Web of Science ®Google Scholar
Liang M. Clinical development of oncolytic viruses in China. Curr Pharm Biotechnol. 2012;13:1852–7. doi:10.2174/138920112800958760. PMID:21740357
PubMed Web of Science ®Google Scholar
Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120:1165–74. doi:10.1182/blood-2012-05-378943. PMID:22730540
PubMed Web of Science ®Google Scholar
Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am. 2015;62:61–73. doi:10.1016/j.pcl.2014.09.006. PMID:25435112
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

CARs on a highway with roadblocks

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

CARs on a highway with roadblocks

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date